Biotech Daily

Wednesday August 19, 2026

Daily news on ASX-listed biotechnology companies

*** ASX DOWN, BIOTECH UP: AVITA UP 23%; AMPLIA DOWN 6.45%**

*** ALCIDION RECORD REVENUE UP 27% TO $52m; PROFIT UP 38% TO $2m**

*** CRYOSITE RECORD REVENUE UP 18% TO $17m; PROFIT UP 19% TO $2m**

*** IMPEDIMED WINS FDA SOZO SARCOPENIA RISK CLEARANCE**

*** SAFETY CLOSES CHIMERIC PHASE I TRIAL; STAFF, COSTS CUT**

*** EYEPOINT: 'DURAVYU MISSES PRIMARY PHASE III WET-AMD ENDPOINT'**

*** AVITA 'PERMEADERM CHEAPER WOUND HEALING'**

*** RECCE R327 DIABETIC FOOT INFECTION STUDY**

*** ENTROPY: 'BIOCINA FOR TRP-8803 PSILOCIN MANUFACTURE'**

*** AUDEARA REQUESTS 'PLACEMENT' TRADING HALT**

*** ATOMO LOSES M-D JOHN KELLY; DIRECTOR DR CHERI WALKER INTERIM**

*** PAUL FIELD REPLACES INVION DIRECTOR ALISTAIR BENNALLACK**

*** ENLITIC LAUNCHES INVESTOR WEB HUB**

MARKET REPORT

The Australian stock market fell 0.18 percent on Wednesday August 19, 2026, with the ASX200 down 16.2 points to 9,053.8 points. Seventeen of the Biotech Daily Top 40 companies were up, 13 fell and 10 traded unchanged.

Avita was the best (see below), up 51 cents or 23.2 percent to $2.71, with 2.0 million shares traded. Medical Developments climbed 6.2 percent; CSL and Resonance rose more than five percent; Alcidion was up 4.6 percent; Micro-X, Optiscan and Proteomics were up more than three percent; Compumedics and Emvision rose two percent or more; EBR, Imugene, Pro Medicus and Starpharma were up more than one percent; with 4D Medical, Clinuvel, Nanosonics, Orthocell, Resmed and Telix up by less than one percent.

Amplia led the falls, down one cent or 6.45 percent to 14.5 cents, with 135,449 shares traded. Paradigm lost 5.6 percent; Lumos fell 4.55 percent; Clarity and Immutep were down more than three percent; Cochlear and Cyclopharm shed two percent or more; Artrya, Mesoblast, Polynovo and Prescient were down more than one percent; with Imricor, Neuren and Saluda down by less than one percent.

ALCIDION GROUP

Alcidion says that record revenue for the year to June 30, 2026 was up 26.6 percent to $51,641,000, with net profit after tax up 38.15 percent to $2,285,000.

Alcidion said its increased revenue from sales and contracts of its Miya Precision hospital management and patient care software and electronic patient record systems was “driven by growth from new and existing customers across the group’s core markets, including customer contract expansion, renewals and new customer acquisitions”.

The company said annual recurring revenue to June 30, rose 34 percent to $38.3 million, including support and maintenance, licence subscriptions and hosting its Miya software; with 37 percent of revenue generated in Australia and New Zealand, and 63 percent from customers in the UK.

The company said it expected revenue in the year to June 30, 2027 to outperform 2025-’26, “underpinned by the increasing momentum evident in the business and the demand from healthcare systems … to support increasing efficiency in care delivery”.

Alcidion chief executive officer Kate Quirke said the year to June 30, 2026 “was a milestone year for the business as we delivered our strongest financial performance to date, whilst increasing the customer base and delivering a record number of go-lives, alongside a strategic acquisition”.

“Across our core and target markets, there is increased demand for our critical enterprise software platform, a demand driven by structural challenges in healthcare that can be addressed through using digital solutions that are inter-operable and intuitive to use,” Ms Quirke said.

The company said diluted earnings per share rose 41.7 percent to 0.17 cents, negative net tangible assets per share fell 94.7 percent to negative 0.01 cents, with cash and cash equivalents of $20,642,000 at June 30, 2026, compared to $17,697,000 at June 30, 2025.

Alcidion was up 0.4 cents or 4.6 percent to 9.1 cents with 4.1 million shares traded.

CRYOSITE

Cryosite says record revenue for the year to June 30, 2026 was up 18.3 percent to $16,700,000, with record net profit after tax up 18.6 percent to $2,235,000.

Cryosite said sales of, and contracts for, its ambient, cold and frozen biologics storage and distribution systems were up 21.5 percent to $12,017,000, ultra-frozen and cryogenic sales and contracts increased 22.6 percent to $2,276,000 and revenue from cord blood and tissue sample storage rose 1.5 percent to $2,407,000.

Cryosite executive director Andrew Kerr said that the year to June 30, 2026 “was a defining year for Cryosite”.

Mr Kerr said the company had delivered on its commitment to secure a second premises without requiring a capital raise “while also achieving record revenue, earnings and operating volume”.

“With record results delivered and our footprint doubled, Cryosite is well positioned for durable long-term growth,” Mr Kerr said.

The company said it had elected not to pay a dividend to shareholders for the second year in a row, compared to a 2.0 cents a share dividend in 2023-’24, with funds to be used to complete the acquisition of its secondary warehouse facility in Auburn, Sydney.

Cryosite said diluted earnings per share rose 94.5 percent to 10.58 cents, with net tangible asset backing per share up 62.9 percent to 5.44 cents.

The company said that it had cash and cash equivalents of $2,244,000 at June 30, 2026 compared to $5,060,000 at June 30, 2025.

Cryosite was untraded at $1.25.

IMPEDIMED

Impedimed says the US Food and Drug Administration 510(k) has cleared its Sozo bio-impedance spectroscopy for sarcopenia risk assessment.
In 2017, Impedimed said the FDA cleared its non-invasive Sozo bio-impedance diagnostic to aid the assessment of unilateral lymphoedema (BD: Aug 14, 2017).
Today, the company said the additional indication allowed Sozo to be used to assess patients at risk of sarcopenia, a disease of low muscle mass or muscle loss.
Impedimed said the clearance made Sozo the only FDA-cleared bio-impedance spectroscopy product for the clinical assessment of sarcopenia risk.
The company said sarcopenia developed in one in three breast cancer patients during chemotherapy as well as impacting patients with chronic conditions such as heart failure and metabolic disorders such as type 2 diabetes or obesity.
Impedimed said the sarcopenia capability would be introduced with a software update for Sozo, expected by 2027.
Impedimed was unchanged at 0.5 cents with 32.3 million shares traded.

CHIMERIC THERAPEUTICS

Chimeric says it will close its phase I/II CHM-2101 gastro-intestinal cancer trial due to safety and has implemented $4 million a year in major cost reductions, including staff.
In 2024, Chimeric said it had enrolled the first of 12 patients in the trial of CDH17 chimeric antigen receptor (CAR) T-cell therapy, or CHM2101, for colorectal and gastric cancer and intestinal neuro-endocrine tumors; and this year began dosing the third cohort at 450 million cells (BD: Jul 22, 2024; Feb 12, 2026).
Today, Chimeric said the safety monitoring committee determined dose level three was unsafe following a second of four patients having “non-fatal dose-limiting toxicities”, including gastro-intestinal fistula, rectal pain and pelvic inflation, adverse events “probably related to CHM-2101 and constituted a dose-limiting toxicity”.
Chimeric said enrolment and dosing of final patients stopped in accordance with the study protocol and existing patients on study would continue to be followed-up.
The company said the anti-tumor activity observed supported CDH17 “as a valid target for further development” but the dose levels required to achieve anti-tumor activity were not tolerated and CHM-2101 would “not be progressed in its current form”.
Chimeric said it was exploring the potential to sell, out-licence or partner the CHM CDH17 asset and program, with a number of companies approached.
Last month, the company said it appointed Hawkesbury Partners to review options available and had spent $80 million in its clinical programs (BD: Jul 1, 2026).
Today, Chimeric said it would reduce headcount, manufacturing and trial-related costs, expected to reduce annualized expenditure by about $4 million.
The company said it intended to negotiate with creditors and its report for the year to June 30 was “expected to include a material uncertainty in relation to going concern”.
The company said discussions were ongoing with parties who had indicated an intention to provide additional funding.
Chimeric chair Bradley Glover said it was a “disappointing outcome”.
“We believe in-vivo delivery provides an opportunity to develop a next-generation CDH17 approach informed by what we have learned clinically, on a faster and lower-cost development path within our existing CDH17 rights,” Mr Glover said. “Our immediate development focus will be on advancing initial feasibility work and evaluating technologies and enhancements that could improve the performance of an in-vivo CDH17 CAR.”
Chimeric fell 1.6 cents or 45.7 percent to 1.9 cents with 13.5 million shares traded.

EYEPOINT PHARMACEUTICALS (FORMERLY PSIVIDA CORP)

Eyepoint says the “primary endpoint [was] not achieved” in its 400-patient, ‘Lugano’ phase III trial of Duravyu for wet age-related macular degeneration (AMD).

Eyepoint said the primary endpoint “a change in baseline in best corrected visual acuity compared to two milligrams of aflibercept … control was not achieved in the full dataset”.

Following the news, Eyepoint fell as much as 73.2 percent from $US14.75 on Friday to a low of $US3.95 on Monday before closing down $US9.88 or 67.0 percent at $US4.87.

Previously, the company said Duravyu, formerly EYP-1901, was the administration of the tyrosine kinase inhibitor, vorolanib, into the eye using its Durasert intra-vitreal, micro-insert drug delivery device (BD: May 7, 2024).

Today, Eyepoint said Duravyu was non-inferior to on-label aflibercept control ($p = 0.0096$) in an ad-hoc analysis, excluding patients who had vision loss unrelated to wet AMD, with no patients experiencing vision loss unrelated to wet AMD in the aflibercept control arm.

Eyepoint said that in similar scale pivotal phase III trials about three-to-five percent of aflibercept patients lost vision, “indicating meaningful overperformance of the on-label aflibercept control group” that contributed to primary endpoint performance.

The company said the trial showed meaningful results for the secondary endpoints including reduced treatment burden, supplement-free rates and safety.

Eyepoint said it expected to report results from its ‘Lucia’ trial of Duravyu for wet AMD by 2027, with a potential US Food and Drug Administration new drug application in 2027.

The company said it was conducting two additional phase III trials of Duravyu in diabetic macular oedema, with enrolment completed and data expected by 2028.

Eyepoint chief executive officer Dr Jay Duker said “the primary endpoint result for the full dataset was unexpected, [but] the consistently positive results from the pre-specified secondary endpoints and the ad hoc analysis on the primary endpoint present a compelling case for Duravyu as a new potential therapeutic option for wet AMD”.

Last year, Opthea said its two phase III trials of OPT-302 with aflibercept or ranibizumab for wet AMD “failed to meet [their] primary endpoint[s]” (BD: Mar 24, 31, 2025).

Overnight on the Nasdaq, Eyepoint closed up 60 US cents or 12.3 percent at $US5.47 ($A7.73) with 15,805,408 shares traded.

AVITA MEDICAL

Avita says a study shows Permeaderm wound treatment had “statistically significant superiority for mean cost per percent total body surface area treated” ($p < 0.001$).

In 2024, Avita said it would commercialize the San Diego, California-based Stedical Scientific’s Permeaderm bio-synthetic wound treatment in the US (BD: Jan 21, 2024).

Today, the company said the multi-centre, randomized, controlled, clinical study enrolled 40 patients in 11 US burn centres with wounds involving up-to 30 percent total body surface area, with patients randomized to receive either its Permeaderm wound matrix or cadaveric allograft prior to split-thickness skin grafting.

Avita said Permeaderm led to “clinically comparable outcomes to cadaveric allograft while reducing product cost by 70 percent”; with mean treatment cost $US149 ($A211) for every one percent of total body surface area for Permeaderm compared with $US497 ($A703) for allograft, a savings of about $US348 ($A492) per percent total body surface area.

Avita said Permeaderm “reduced preparation time by 95.7 percent compared with allograft by eliminating tissue tracking, thawing and meshing while maintaining comparable application time in the operating room” and outcomes were comparable between treatment groups, and no adverse events attributed to Permeaderm.

Avita was up 51 cents or 23.2 percent to $2.71 with two million shares traded.

RECCE PHARMACEUTICALS

Recce says it has ethics approval to add eight patients and a comparator protocol to its 200-patient, phase III trial of R327 gel for diabetic foot infections.

Earlier this year, Recce said it had ethics approval for a 200-patient, phase III trial of R327G topical gel for diabetic foot ulcer infections in Australia (BD: Jun 22, 2026).

Today, Recce managing-director James Graham told Biotech Daily that "because of the strong efficacy and safety data from this open label study … moving to the comparator version of the protocol will enrol 208 patients in total".

"This phase of study is based on the data to date and represents a pivotal study on which to base regulatory filings," Mr Graham said.

The company said phase III dosing was "underway, with active recruitment and treatment including mild-to-moderate [diabetic foot infection] patients continuing to progress".

Recce said the approved amendment added a randomized, active-controlled, non-inferiority study in diabetic foot infection, with the 208 participants randomized between R327 gel and a physician-selected antibiotic, allowing it to generate "comparative clinical data for R327 against established antibiotic treatment options".

The company said the amended inclusion criteria allowed patients randomized to R327 to receive treatment for each qualifying diabetic foot infection they experienced during the study, allowing multiple efficacy assessments to be captured per patient.

Recce said the updated protocol introduced "digital wound photography for standardized, objective wound measurement".

The company said a planned interim analysis would be conducted by an independent data monitoring committee after 104 participants were enrolled, randomized, treated and followed to end of treatment or withdrawn.

Mr Graham said the protocol amendment reflected "the significant advancements being made in our phase III clinical programs, with continued engagement from trial sites and clinicians".

"R327 has the potential to become the first standard-of-care used by physicians for the treatment of [diabetic foot infections]," Mr Graham said.

Recce was up half a cent or 1.3 percent to 38.5 cents.

ENTROPY NEURODYNAMICS (FORMERLY TRYPTAMINE THERAPEUTICS)

Entropy says it has appointed Adelaide's Biocina as its contract development and manufacturing organization to produce TRP-8803 intra-venous psilocin for clinical trials.

Entropy said Biocina provided end-to-end drug substance and drug product manufacturing from clinical development through commercial supply and held an Australian Therapeutic Goods Administration licence for controlled substances and maintained the regulatory framework required to handle substances including psilocin.

Earlier this year, the company said the six-patient, first cohort of its phase I trial showed TRP-8803 psilocin led to a 100 percent clinically meaningful improvement for binge eating disorder; and later, said it had ethics committee approval to begin a 72-patient, phase Ib/IIa study of TRP-8803 in eight indications (BD: Jul 7, Aug 4, 2026).

Previously, the then Tryptamine said that psilocin was the active psychedelic metabolite of psilocybin found in 'magic mushrooms' (BD: Jul 1, 2024).

Today, Entropy said the agreement was "a critical component of the company's phase II/III trial and commercialization strategy".

The company said Biocina would produce TRP-8803 at its Perth facility, with manufacturing expected to take 24 weeks and stability studies continuing for 24 months.

Entropy was up 0.05 cents or 1.35 percent to 3.75 cents with 2.1 million shares traded.

AUDEARA

Audeara has requested a trading halt “pending an announcement regarding a material private placement”.
Trading will resume on August 21, 2026, or on an earlier announcement.
Audeara last traded at 3.3 cents.

ATOMO DIAGNOSTICS

Atomo says co-founding managing-director John Kelly will step down, effective from today, with US-based director Dr Cheri Walker as interim chief executive officer.
Atomo said Mr Kelly would step down as both a director and chief executive officer “following a board decision to reposition the company’s leadership to reflect its evolving international commercial footprint”.
The company said as a co-founder Mr Kelly was “key in developing the company’s core technology, launching its initial award-winning HIV product, securing its listing, and establishing its commercial platform internationally … [with] the majority of the company's commercial activity and potential concentrated in the US and Europe”.
Atomo said it had “determined that considering a transition of the managing-director and [chief executive officer] to a global position is better aligned with the company’s operational and commercial structure moving forward and has resolved to explore transition executive leadership closer to its core markets”.
In 2022, Atomo said it had appointed Dr Walker as a director (BD: Nov 15, 2022).
Today, the company said Dr Walker had more than 25 years of experience in public and private sector and that her US base reflected “the board’s acknowledgement to better align executive leadership with the company’s primary commercial markets”.
Atomo said it would begin “a formal global search process to appoint a permanent [chief executive officer] in due course” with Mr Kelly to support Dr Walker in the interim to “ensure continuity of leadership and facilitating the transfer of knowledge”.
The company said Dr Walker would be paid a $222,500 six-monthly salary as well as her non-executive director fees.
Atomo said it thanked Mr Kelly for his “foundational contribution in building the company from inception to its current international scale”.
Atomo was unchanged at 1.8 cents with 6.2 million shares traded.

INVION

Invion says it has appointed Paul Field as an independent non-executive director, effective immediately, following the retirement of Alistair Bennallack.
Invion said Mr Field had more than 30 years of experience in the biopharmaceutical industry, had worked for Neurizon (formerly Pharmaust), Horizon 3 Healthcare Fund and other biotechnology companies and was currently a 60 Degrees Pharmaceuticals director, Wintermute Biomedical executive chair and Alsonex head of business development.
According to his Linkedin page, Mr Field held a Bachelor of Arts from the University of Sydney and a Master of Arts from Charlottesville’s University of Virginia.
The company said Mr Bennallack had served on the board since 2020 “with dedication and professionalism during a period of significant operational and clinical progress” and thanked him for his “valuable contribution and wishes him well in his future endeavors”.
Invion was unchanged at 3.7 cents.

ENLITIC

Enlitic says it has opened an investor hub website to “build direct, interactive relationships with … shareholders” to provide content and communications on a single platform.

Enlitic said the website allowed investors to follow its progress as it advances the commercialization of its artificial intelligence (A.I.)-powered healthcare data systems.

The company said it would publish regular updates on the website, including videos, announcements, interviews, product and partnership updates and research.

Enlitic said sign-up for the website was available at: https://enlitic.com/auth/signup.

Enlitic was up 0.1 cents or 25 percent to 0.5 cents with 55.2 million shares traded.